A Phase 4 interventional study of Vildagliptin and Sitagliptin in Diabetes Mellitus Type 2, sponsored by Novartis Pharmaceuticals. Completed at 11 sites in Germany. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-03-02.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Vildagliptin · Diabetes Mellitus, Type 2.
Among the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2, this one is the 84th largest by enrollment of the 118 interventional ones that give a count, is one of 10 that started in 2012, is one of 43 in phase 4, and was the 90th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Vildagliptin: first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
119 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 65 · Phase 4 43
First in 2003; this study’s year is marked. 10 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 51 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 162 across the 118 interventional studies. Of the 113 that completed or were terminated, 13 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
91 of 119 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
122 studies in Diabetes Mellitus, Type 2 by Novartis: none open now, none under way, none of them phase 3. Of 121 finished, 27 (22%) have results posted.
Among the 122 studies in Diabetes Mellitus, Type 2 by Novartis, this one is the 90th largest by enrollment of the 121 interventional ones that give a count, is one of 7 that started in 2012, is one of 30 in phase 4, and was the 106th registered.
Novartis’s Diabetes Mellitus, Type 2 studies by the year they started, since 1992.
None of the studies under way reaches primary completion within a year.
Among the 119 studies testing vildagliptin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 122 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Vildagliptin and Sitagliptin both belong to the class of DPP-4 inhibitors, but differ in their pharmacokinetic profile as well as in their approved application (Vildagliptin, 2x 50 mg daily, Sitagliptin, 1x 100 mg daily). This leads to distinct results regarding postprandial blood-glucose normalization as well as protective properties regarding hypoglycemic episodes - especially during the night. Additionally, in type 1 diabetic patients a correlation has been described between hypoglycemia and abnormal heart function (QTc-elongation), which can have severe consequences for the patients. This study aims for the evaluation of the potency of both drugs to prevent and/or reduce hypoglycemic events in insulin-dependent type-2 diabetics and furthermore to evaluate the correlation of hypoglycemic episodes with changes in heart-function measured by Holter-ECG.
The hypothesis is tested, if vildagliptin leads to a more favourable glycemic profile than sitagliptin and is more potent in protecting from nocturnal abnormalities in heart-function caused by undetected hypoglycemic episodes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Written must be obtained before any assessment is performed.
Exclusion Criteria:
FPG ≥ 270 mg/dL (15 mmol/L) at Visit 1. 2. Use of any of the following medications as assessed at Visit 1:
treatment with any drug of known and frequent toxicity to a major organ, or that may interfere with the interpretation of the efficacy and safety data during the study.
<!-- -->
hepatic disorder defined as:
acute infections which may affect blood glucose control within the past 4 weeks.
<!-- -->
clinically significant laboratory abnormalities which, in the opinion of the investigator, cause the patient to be considered inappropriate for inclusion in the study.
<!-- -->
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: vildagliptin 50mg BID for 8 weeks; followed by Washout then Period 2: sitagliptin 100mg QD for 8 weeks
Drug: Vildagliptin · Drug: Sitagliptin
Period 1: sitagliptin 100mg QD for 8 weeks; followed by Washout then Period 2: vildagliptin 50mg BID for 8 weeks
Drug: Vildagliptin · Drug: Sitagliptin
vildagliptin 50mg BID for 8 weeks
Also known as: Vildagliptin (Galvus) LAF237
sitagliptin 100mg QD for 8 weeks
Also known as: sitagliptin, Januvia
Hypoglycemic Profile of Vildagliptin Compared to Sitagliptin Over 4 Days After 8 Weeks of Treatment in Period 1 & 2
The hypoglycemic profile is defined as the area under the curve glucose-time profile obtained by continuous glucose monitoring Interstitial glucose values below 3.9 mmol/L (averaged over 5 minutes) were considered relevant for the estimation of the interstitial glucose AUC in the hypoglycemic range These AUC\<3.9mmol/L/5min. values were summed up over 4 days (unit: mmol/L/4d) or over 24 hours at measurement Days 2, 3, 4, and 5 (unit: mmol/L/24h). Lower values for AUC reflect less intense hypoglycemia.
Time frame: baseline and 0-24 hours post-dose on Days 2 to 5
Number of Hypoglycemic Events During Vildagliptin Treatment Compared to Sitagliptin Treatment.
Hypoglycemic events are defined as blood glucose values \<70 mg/dL measured by a self-monitored blood glucose (SMBG) or continuous glucose monitoring (CGM) measurement regardless of any symptoms suggestive of low blood glucose.
Time frame: after 8 weeks period 1 and Period 2
Mean Duration of Hypoglycemic Events (Min.) Measured With Continuous Glucose Monitoring (CGM) Over 4 Days After 8 Weeks of Treatment for Period 1 & Period 2
the mean duration of hypoglycemic events is detected by continuous glucose monitoring (CGM)measurement.
Time frame: after 8 weeks for Period 1 & Period 2
Mean Amplitudes of Hypoglycemic Events (mmol/L) Measured With Continuous Glucose Monitoring (CGM) Over 4 Days After 8 Weeks of Treatment for Period 1 & Period 2
To evaluate by CGM measurement the grade of severity of hypoglycemia measured as the mean amplitude over 4 days after 8 weeks of treatment in Period 1 \& Period 2
Time frame: after 8 weeks Period 1 & Period 2
Number of Severe Hypoglycemic Events During Vildagliptin Treatment Compared to Sitagliptin Treatment After 8 Weeks of Treatment in Period 1 and Period 2
Severe hypoglycemic events are defined as any episode requiring the assistance of another party or measured plasma glucose levels of \<40 mg /dL. Assessed by self-monitored blood glucose (SMBG)After 8 weeks of treatment in Period 1 and Period 2
Time frame: after 8 weeks Period 1 & Period 2
Glucose Fluctuations During the Day Under Vildagliptin Treatment Compared to Sitagliptin Treatment on Day 2 After 8 Weeks of Treatment Period 1 & Period 2
Glucose fluctuations are assessed by the mean amplitude of glycemic excursions (MAGE) and standard deviations (SD) (Service et al., 1970). on day 2 after 8 weeks of treatment Period 1 \& Period 2
Time frame: Day 2 after 8 weeks of treatment Period 1 & Period 2
Number of Participants With ECG Abnormalities Depending on Hypoglycemic Events After 8 Weeks of Treatment Period 1 & Period 2
ECG abnormalities are defined as either: • Occurrence of \>30 ventricular extrasystoles (VES) per hour or • Occurrence of ≥2 consecutive VES (Couplets) or • Occurrence of ≥3 consecutive VES (Triplets) or • QT-time corrected for heart rate (QTc) \>440 ms. after 8 weeks of treatment Period 1 \& Period 2
Time frame: after 8 weeks of treatment Period 1 & Period 2
Change From Baseline of Inflammatory Biomarkers High Sensitivity C-reactive Protein (hsCRP) After 8 Weeks of Treatment in Period 1 & Period 2
The inflammatory biomarkers hsCRP was assessed at baseline and after 8 weeks of treatment Period 1 \& Period 2
Time frame: Baseline, after 8 weeks Period 1 & Period 2
Change From Baseline of Inflammatory Biomarkers Interleukin 6 (IL-6) After 8 Weeks of Treatment in Period 1 & Period 2
The inflammatory biomarkers IL-6 was assessed at baseline and after 8 weeks of treatment Period 1 \& Period 2
Time frame: Baseline, after 8 weeks Period 1 & Period 2
Percentage Change From Baseline of Pro-insulin/C-peptide Ratios After 8 Weeks of Treatment Period 1 & Period 2
Percentage Change from baseline of pro-insulin/C-peptide ratios after 8 weeks of treatment Period 1 \& Period 2 Higher pro-insulin / C-peptide ratios (expressing disproportional hyperproinsulinemia) may be associated with increasing beta cell dysfunction and more inefficient pro-insulin processing
Time frame: Baseline, after 8 weeks Period 1 & Period 2
Number of Occurrence of Pre-defined ECG Findings During 4 Days of Continuous ECG Monitoring at Baseline and in the 8th Week of Periods 1 and 2
Number of Occurrence of pre-defined ECG findings during 4 days of continuous ECG monitoring at baseline and in the 8th week of Periods 1 and 2. ECG data were continuously recorded and analyzed over a period of 4 days simultaneously with continuous glucose monitoring. It assessed number of any Vertical Electric(al) Sounding (VES), number of 2 consecutive VES \[couplets\], and number of \>3 consecutive VES \[salves\]
Time frame: after 8 weeks Period 1 & Period 2
Period 1: 8 weeks treatment with vildagliptin 50mg BID or sitagliptin 100mg QD, 1-4 weeks wash-out, followed by Period 2, 8 weeks treatment with sitagliptin 100mg QD or vildagliptin 50mg BID
| Milestone | Vildagliptin Followed by Sitagliptin | Sitagliptin Followed by Vildagliptin |
|---|---|---|
| Started | 25 | 26 |
| Completed | 24 | 25 |
| Not completed | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 |
| Milestone | Vildagliptin Followed by Sitagliptin | Sitagliptin Followed by Vildagliptin |
|---|---|---|
| Started | 24 | 25 |
| Completed | 24 | 25 |
| Not completed | 0 | 0 |
The hypoglycemic profile is defined as the area under the curve glucose-time profile obtained by continuous glucose monitoring Interstitial glucose values below 3.9 mmol/L (averaged over 5 minutes) were considered relevant for the estimation of the interstitial glucose AUC in the hypoglycemic range These AUC\<3.9mmol/L/5min. values were summed up over 4 days (unit: mmol/L/4d) or over 24 hours at measurement Days 2, 3, 4, and 5 (unit: mmol/L/24h). Lower values for AUC reflect less intense hypoglycemia.
| mmol/L/4d | Vitagliptin | Sitagliptin |
|---|---|---|
| Hypoglycemic Profile of Vildagliptin Compared to Sitagliptin Over 4 Days After 8 Weeks of Treatment in Period 1 & 2 | 11.2 ± 25.65 | 5.3 ± 11.70 |
Hypoglycemic events are defined as blood glucose values \<70 mg/dL measured by a self-monitored blood glucose (SMBG) or continuous glucose monitoring (CGM) measurement regardless of any symptoms suggestive of low blood glucose.
| number of hypoglycemic events | Vitagliptin | Sitagliptin |
|---|---|---|
| continuous glucose monitoring (CGM) | 69 | 37 |
| self-monitored blood glucose (SMBG) | 29 | 13 |
the mean duration of hypoglycemic events is detected by continuous glucose monitoring (CGM)measurement.
| minutes | Vitagliptin | Sitagliptin |
|---|---|---|
| Mean Duration of Hypoglycemic Events (Min.) Measured With Continuous Glucose Monitoring (CGM) Over 4 Days After 8 Weeks of Treatment for Period 1 & Period 2 | 29.1 ± 44.71 | 28.0 ± 51.45 |
To evaluate by CGM measurement the grade of severity of hypoglycemia measured as the mean amplitude over 4 days after 8 weeks of treatment in Period 1 \& Period 2
| mmol/L | Vitagliptin | Sitagliptin |
|---|---|---|
| Mean Amplitudes of Hypoglycemic Events (mmol/L) Measured With Continuous Glucose Monitoring (CGM) Over 4 Days After 8 Weeks of Treatment for Period 1 & Period 2 | 0.2 ± 0.32 | 0.2 ± 0.36 |
Severe hypoglycemic events are defined as any episode requiring the assistance of another party or measured plasma glucose levels of \<40 mg /dL. Assessed by self-monitored blood glucose (SMBG)After 8 weeks of treatment in Period 1 and Period 2
| severe hypoglycemic events | Vitagliptin | Sitagliptin |
|---|---|---|
| Number of Severe Hypoglycemic Events During Vildagliptin Treatment Compared to Sitagliptin Treatment After 8 Weeks of Treatment in Period 1 and Period 2 | 1 | 1 |
Glucose fluctuations are assessed by the mean amplitude of glycemic excursions (MAGE) and standard deviations (SD) (Service et al., 1970). on day 2 after 8 weeks of treatment Period 1 \& Period 2
| mmol/L | Vitagliptin | Sitagliptin |
|---|---|---|
| Glucose Fluctuations During the Day Under Vildagliptin Treatment Compared to Sitagliptin Treatment on Day 2 After 8 Weeks of Treatment Period 1 & Period 2 | 4.7 ± 1.69 | 4.6 ± 1.36 |
ECG abnormalities are defined as either: • Occurrence of \>30 ventricular extrasystoles (VES) per hour or • Occurrence of ≥2 consecutive VES (Couplets) or • Occurrence of ≥3 consecutive VES (Triplets) or • QT-time corrected for heart rate (QTc) \>440 ms. after 8 weeks of treatment Period 1 \& Period 2
| participants | Vitagliptin | Sitagliptin |
|---|---|---|
| Patients with hypoglycemia (n=21,17) | 14 | 10 |
| Patients without hypoglycemia (n=28,32) | 19 | 24 |
The inflammatory biomarkers hsCRP was assessed at baseline and after 8 weeks of treatment Period 1 \& Period 2
| mg/L | Vitagliptin | Sitagliptin |
|---|---|---|
| Change From Baseline of Inflammatory Biomarkers High Sensitivity C-reactive Protein (hsCRP) After 8 Weeks of Treatment in Period 1 & Period 2 | 0.79 ± 4.96 | 0.60 ± 2.48 |
The inflammatory biomarkers IL-6 was assessed at baseline and after 8 weeks of treatment Period 1 \& Period 2
| pg/L | Vitagliptin | Sitagliptin |
|---|---|---|
| Change From Baseline of Inflammatory Biomarkers Interleukin 6 (IL-6) After 8 Weeks of Treatment in Period 1 & Period 2 | 0.40 ± 3.90 | 0.08 ± 0.93 |
Percentage Change from baseline of pro-insulin/C-peptide ratios after 8 weeks of treatment Period 1 \& Period 2 Higher pro-insulin / C-peptide ratios (expressing disproportional hyperproinsulinemia) may be associated with increasing beta cell dysfunction and more inefficient pro-insulin processing
| Percentage Change | Vitagliptin | Sitagliptin |
|---|---|---|
| Percentage Change From Baseline of Pro-insulin/C-peptide Ratios After 8 Weeks of Treatment Period 1 & Period 2 | -0.34 ± 0.47 | -0.31 ± 0.57 |
Number of Occurrence of pre-defined ECG findings during 4 days of continuous ECG monitoring at baseline and in the 8th week of Periods 1 and 2. ECG data were continuously recorded and analyzed over a period of 4 days simultaneously with continuous glucose monitoring. It assessed number of any Vertical Electric(al) Sounding (VES), number of 2 consecutive VES \[couplets\], and number of \>3 consecutive VES \[salves\]
| number of occurrence | Vitagliptin | Sitagliptin |
|---|---|---|
| # any VES Per.1 n=23, 25 | 879.7 ± 1405.2 | 2786.7 ± 6507.7 |
| # any VES Per.2 n=25, 23 | 4389.9 ± 16692 | 1060.2 ± 1812.4 |
| # couplets VES Per.1 n=23, 25 | 12.8 ± 32.5 | 115.0 ± 405.9 |
| # couplets VES Per.2 n=25, 23 | 6.7 ± 10.3 | 2.4 ± 3.0 |
| # salves VES Per.1 n=23, 25 | 1.0 ± 2.4 | 15.8 ± 52.6 |
| # salves VES Per.2 n=25, 23 | 0.8 ± 1.7 | 0.9 ± 1.9 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vildagliptin | — | 2/50 (4%) | 16/50 (32%) |
| Sitagliptin | — | 1/50 (2%) | 9/50 (18%) |
| Event | Vildagliptin | Sitagliptin |
|---|---|---|
| CORONARY ARTERY DISEASECardiac disorders | 1/50 | 0/50 |
| MYOCARDIAL INFARCTIONCardiac disorders | 1/50 | 0/50 |
| PERICARDITISCardiac disorders | 1/50 | 0/50 |
| HYPOGLYCAEMIAMetabolism and nutrition disorders | 0/50 | 1/50 |
| LUNG NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/50 | 0/50 |
| TRANSIENT ISCHAEMIC ATTACKNervous system disorders | 0/50 | 1/50 |
| Event | Vildagliptin | Sitagliptin |
|---|---|---|
| HYPOGLYCAEMIAMetabolism and nutrition disorders | 13/50 | 7/50 |
| BLOOD GLUCOSE DECREASEDInvestigations | 4/50 | 3/50 |
| Age, Continuous(years) | Vildagliptin Followed by Sitagliptin | Sitagliptin Followed by Vildagliptin | Total |
|---|---|---|---|
| Mean | 64.8 ± 6.0 | 65.2 ± 8.6 | 65 ± 7.4 |
| Sex: Female, Male(Participants) | Vildagliptin Followed by Sitagliptin | Sitagliptin Followed by Vildagliptin | Total |
|---|---|---|---|
| Female | 4 | 6 | 10 |
| Male | 21 | 20 | 41 |
The record gives a start of Nov 2012, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vildagliptin · Sitagliptin